omniture
logo
Search
浙江博锐生物制药有限公司
Media Room

Latest News

rss

BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate

SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as ...

2023-11-07 14:14 1348

Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection Receives U.S. FDA Approval

SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as...

2023-10-24 15:05 1187

Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China

SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Recently, BioRay Pharmaceutical Co., Ltd.  (hereinafter re...

2023-09-13 14:24 1432

BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1

SHANGHAI, May 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as ...

2023-05-24 16:14 1924